Bausch Health Companies Inc (NYSE:BHC) EVP Sells $76,734.10 in Stock
Bausch Health Companies Inc (NYSE:BHC) EVP Christina Ackermann sold 3,418 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $22.45, for a total transaction of $76,734.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Christina Ackermann also recently made the following trade(s):
- On Thursday, July 11th, Christina Ackermann sold 3,968 shares of Bausch Health Companies stock. The stock was sold at an average price of $24.81, for a total transaction of $98,446.08.
Shares of NYSE:BHC traded up $0.39 during trading on Tuesday, reaching $22.69. 2,352,996 shares of the company traded hands, compared to its average volume of 3,925,029. The company has a fifty day simple moving average of $23.95. The firm has a market cap of $7.80 billion, a price-to-earnings ratio of 5.64, a P/E/G ratio of 0.27 and a beta of 0.76. Bausch Health Companies Inc has a 1-year low of $17.20 and a 1-year high of $28.45. The company has a current ratio of 1.21, a quick ratio of 0.92 and a debt-to-equity ratio of 8.94.
Hedge funds have recently added to or reduced their stakes in the stock. Citizens Financial Group Inc RI acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at $28,000. Investors Research Corp lifted its stake in shares of Bausch Health Companies by 85.7% in the 2nd quarter. Investors Research Corp now owns 1,300 shares of the company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $38,000. Providence Capital Advisors LLC acquired a new stake in shares of Bausch Health Companies in the 1st quarter valued at $49,000. Finally, Asset Planning Services Ltd. acquired a new stake in shares of Bausch Health Companies in the 2nd quarter valued at $55,000. 53.70% of the stock is owned by institutional investors and hedge funds.
BHC has been the topic of several recent research reports. Barclays set a $28.00 price target on shares of Bausch Health Companies and gave the stock a “buy” rating in a research report on Monday, July 8th. Cantor Fitzgerald set a $32.00 price objective on shares of Bausch Health Companies and gave the stock a “buy” rating in a research note on Friday, May 31st. Wells Fargo & Co reaffirmed a “sell” rating on shares of Bausch Health Companies in a research note on Monday, July 15th. ValuEngine raised shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a research note on Monday, July 29th. Finally, HC Wainwright lifted their target price on shares of Bausch Health Companies from $50.00 to $54.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $29.68.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Further Reading: What is Call Option Volume?
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.